| answer text |
<p>The Medicines and Healthcare products Regulatory Agency has monitored suspected
reports of cerebral haemorrhage and thrombosis following COVID-19 vaccination. No
direct association between reports of cerebral haemorrhage and the AstraZeneca or
Pfizer COVID-19 vaccines has been identified in women or men aged either above or
below 60 years old. However, a review of reports of specific types of blood clot in
cerebral veins, occurring with low platelets concluded that a link with AstraZeneca
vaccine is likely. Cerebral hemorrhage may occur because of these events. No link
has been identified with the Pfizer vaccine.</p><p>There is some evidence that the
reported incidence rate of these blood clots is slightly higher in females compared
to men, although this is not seen across all age groups. A higher reported incidence
rate is seen in younger adult age groups following the first dose compared to the
older groups at 21.1 per million doses in those aged 18 to 49 years old and 11.0 per
million doses in those aged 50 years old and over. There does not appear to be an
increased risk following the second dose of the AstraZeneca vaccine. The advice remains
that the benefits of the COVID-19 vaccines outweigh the risks for the majority of
people.</p>
|
|
